PHARMACISTS have until tomorrow, 06 Jun to provide input to a controversial review (PD 30 Jan 17) that has called into question the way ezetimibe is prescribed and dispensed to patients with high cholesterol who are inadequately controlled on, or unable to tolerate, statin therapy.
MSD, the manufacturer and marketer of ezetimibe, has declared that the draft Department of Health Post-market Review of ezetimibe is flawed and if acted upon, could result in a number of unintended consequences, including the possibility of the delisting of ezetimibe in Australia.
The draft proposal recommends significant price cuts for the drug which are based on only two years of data rather than a broader perspective of the past decade of statin use, MSD argues.
Visit pbs.gov.au to submit.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Jun 17
